Celularity Inc.: quarterly results

CELUNASDAQHealthcare · Pharmaceutical Preparations

Price

$0.63

November 13, 2026Market cap $20M

What Ploutos Investor adds for Celularity

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 6 fiscal years, from 2020
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has fallen 50% since Oct 20, 2026, when the 10-Q these figures come from was filed ($1.26 then, $0.63 on Nov 13, 2026). The figures date from before that move.10-Q
  • A figure that did not match the numbers it is built from has been left out.

Results, quarter by quarter

When the company put out each quarter's results (its 8-K, item 2.02), what they showed against the same quarter a year before, and how the stock moved on the first session after.

Oct 20, 2026 last results

Next results

in 14 daysAround Nov 30, 2026 · for Q3 2026

last Oct 20, 2026next Nov 30, 2026

A rough estimate from when it has reported before, which has varied. The company announces the date itself.

The first session after results

±6.2%average move, either way

1 times upof the last 43 times down

Largest: -19.0% on Oct 21, 2026 (Q2 2026).

How the stock moved after each release

The close of the first session after the results against the close before them.

CELU that sessionS&P 500 the same day

Every release

Revenue and diluted EPS of the quarter reported, with the change against the same quarter a year before.

  • Q2 2026
    Stock, next session-19.0%
  • Q1 2026
    Stock, next session-1.5%
  • Q4 2025
    Stock, next session+2.5%
  • Q3 2025
    Stock, next session-1.9%

Every release

CELU's results days and the share's move after each, from Q2 2021 to Q2 2025, 17 more quarters

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 8 quarters.

Times are the SEC's acceptance of the 8-K, in New York time: before 16:00 the market traded on it that day, after it the next day. A move on a results day has other causes too, and says nothing about the next one. Where a 10-Q or 10-K is named, the results came only in that report: the company put out no press release (8-K) for them.

The full analysis

What do Celularity's filings show?

The results say what Celularity reported. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.